Challenges to Precision Medicine for Anti-Cancer Immunotherapy: When Other Combos w/ Anti-PD-1 Are Active, Mechanisms May Be Redundant w anti-CTLA-4

1,041 views
November 28, 2019
2 Comments
Login to view comments. Click here to Login